Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Net Margin (2022 - 2025)

Taysha Gene Therapies' Net Margin history spans 4 years, with the latest figure at 1353.58% for Q2 2025.

  • For Q2 2025, Net Margin rose 52844.0% year-over-year to 1353.58%; the TTM value through Sep 2025 reached 1583.66%, down 135399.0%, while the annual FY2024 figure was 1071.62%, 34956.0% down from the prior year.
  • Net Margin for Q2 2025 was 1353.58% at Taysha Gene Therapies, down from 935.23% in the prior quarter.
  • Across five years, Net Margin topped out at 7487.65% in Q1 2022 and bottomed at 2467.07% in Q3 2023.
  • The 4-year median for Net Margin is 817.21% (2024), against an average of 543.43%.
  • The largest annual shift saw Net Margin crashed -786211bps in 2023 before it skyrocketed 103955bps in 2024.
  • A 4-year view of Net Margin shows it stood at 4220.54% in 2022, then plummeted by -69bps to 1324.67% in 2023, then tumbled by -170bps to 929.03% in 2024, then plummeted by -46bps to 1353.58% in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Net Margin are 1353.58% (Q2 2025), 935.23% (Q1 2025), and 929.03% (Q4 2024).